Tuesday, March 31, 2015: 8:00 AM-9:20 AM
International Ballroom (Hilton Chicago)
Description: In this session data will be presented from human trials of novel therapeutic approaches for ovarian cancer. PARP inhibition, immune modulators, and anti-vascular strategies will be discussed, in addition to a cost-effectiveness analysis of targeted treatment. The scientific presentations will be followed by a lively analysis and discussion by a panel of experts in the field.
Moderators: Xiaohua Wu, MD, Fudan University Shanghai Cancer Center, Shanghai, China and Jason Konner, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
8:05 AM
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study
L. M. Landrum1, W. E. Brady2, D. K. Armstrong3, K. N. Moore1, P. A. DiSilvestro4, D. M. O'Malley5, M. E. Tenney6, P. G. Rose7 and P. M. Fracasso8
1The University of Oklahoma, Oklahoma City, OK, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Johns Hopkins Kimmel Cancer Center, Baltimore, MD, 4Women & Infants Hospital, Brown University, Providence, RI, 5The Ohio State University, Columbus, OH, 6University of Chicago, Chicago, IL, 7Cleveland Clinic, Cleveland, OH, 8University of Virginia, Charlottesville, VA
8:16 AM
Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab
J. Hamanishi1, M. Mandai2, N. Matsumura1, K. Abiko1, T. Baba1, K. Yamaguchi1 and I. Konishi1
1Kyoto University, Kyoto, Japan, 2Kinki University, Osakasayama, Japan
8:27 AM
A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: a Gynecologic Oncology Group study
K. N. Moore1, M. Sill2, M. E. Tenney3, C. J. Darus4, D. Griffin5, T. L. Werner6, S. E. Waggoner7 and R. J. Behrens8
1The University of Oklahoma, Oklahoma City, OK, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Chicago, Chicago, IL, 4Maine Medical Partners, Scarborough, ME, 5Anmed Gynecologic Oncology/Upstate Oncology Associates, Anderson, SC, 6University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, 7University Hospitals Case Medical Center, Cleveland, OH, 8Iowa Oncology Research Association, Des Moines, IA
8:49 AM
Panel Discussion - Monk
B. J. Monk1, D. L. Richardson2, J. F. Liu3 and R. L. Coleman4
1University of Arizona Cancer Center, Phoenix, AZ, 2University of Texas Southwestern Medical Center, Dallas, TX, 3Dana-Farber Cancer Institute, Boston, MA, 4The University of Texas MD Anderson Cancer Center, Houston, TX
9:21 AM
Panel Discussion
B. J. Monk
University of Arizona Cancer Center, Phoenix, AZ
9:21 AM
Introductory Remarks
J. Konner1 and X. Wu2
1Memorial Sloan-Kettering Cancer Center, New York, NY, 2Fudan University Shanghai Cancer Center, Shanghai, China
